Tower Research Capital LLC (Trc) Actinium Pharmaceuticals, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $3.39 Billion
- Q3 2025
A detailed history of Tower Research Capital LLC (Trc) transactions in Actinium Pharmaceuticals, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 555 shares of ATNM stock, worth $721. This represents 0.0% of its overall portfolio holdings.
Number of Shares
555
Previous 2,478
77.6%
Holding current value
$721
Previous $3,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
21 transactions
Others Institutions Holding ATNM
# of Institutions
64Shares Held
6.8MCall Options Held
42.3KPut Options Held
0-
Black Rock Inc. New York, NY1.88MShares$2.44 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.38MShares$1.8 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny625KShares$812,1060.0% of portfolio
-
Acadian Asset Management LLC Boston, MA490KShares$636,4500.0% of portfolio
-
Geode Capital Management, LLC Boston, MA328KShares$426,9440.0% of portfolio
About Actinium Pharmaceuticals, Inc.
- Ticker ATNM
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,184,700
- Market Cap $32.7M
- Description
- Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...